all report title image
  • Published On : Jun 2022
  • Code : CMI5041
  • Industry : Pharmaceutical
  • Pages : 370
  • Formats :

Peanut allergies are an overreaction of the immune system to peanuts. A peanut allergy is one of the most common types of food allergies. Infants with eczema and/or egg allergy are more likely to develop a peanut allergy. Among all food allergies, peanut allergy is the most common, and individual with a peanut allergy are at a greater risk for anaphylaxis

The North America, Europe, and Australia Peanut Allergy Treatment Market is estimated to be valued at US$ 1,252.6 million in 2022 and is expected to exhibit a CAGR of 11.7% during the forecast period (2022-2030).

Figure 1.North America, Europe, and Australia Peanut Allergy Treatment Market Share (%) in Terms of Value, By Drug Type, 2022

North America, Europe, and Australia Peanut Allergy Treatment  | Coherent Market Insights

Increasing prevalence of peanut allergy is expected to drive market growth during the forecast period.

Increasing prevalence of peanut allergy is expected to drive growth of the North America, Europe, and Australia peanut allergy treatment market over the forecast period. For instance, According to a factsheet provided by Allergy UK, is a British medical charity dedicated to helping adults and children with their allergies, in July 2021, Peanut allergy affected around 2% of children in the UK. Peanuts are a common cause of food allergy. It usually develops in early childhood but, sometimes, peanut allergy can appear in adult age. Peanut allergy remains constant and only approximately 1 in 5 children outgrow their allergy by 10 years of age.

CMI table icon

North America, Europe, and Australia Peanut Allergy Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,252.6 Mn
Historical Data for: 2017-2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 11.7% 2030 Value Projection: US$ 3,036.9 Mn
Geographies covered:
  • North America: U.S.,  Northeast,  Southwest,  West,  Southeast,  Midwest and Canada
  • Europe: U.K., Germany, France, Italy,  Spain,  Switzerland,  Netherlands,  Austria,  Czech & Slovakia, and Rest of Europe
  • Australia
Segments covered:
  • By Drug Type: Epinephrine, Antihistamine (Loratadine, Diphenhydramine, Others), Palforzia, Pipeline Drugs (Viaskin Peanut, Ligelizumab, CA002, PRT120, Dupilumab)
  • By Route of Administration: Oral, Parenteral, Intranasal, Epicutaneous
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

DBV Technologies, Aimmune Therapeutics, Inc., Prota Therapeutics Pty Ltd., COUR Pharmaceuticals, BlueWillow Biologics, HAL Allergy B.V., Allergy Therapeutics PLC., Novartis AG, Regeneron Pharmaceuticals, Inc., Vedanta Biosciences, Inc., Cambridge Allergy Ltd. (Camallergy), Angany Inc., Moonlight Therapeutics Inc., Allero Therapeutics B.V., Sanofi, Johnson & Johnson, Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Bayer AG, Aurobindo Pharma Limited., Astellas Pharma Inc., Siolta Therapeutics, DESENTUM OY, ALK, Immunomic Therapeutics, Inc., Stallergenes Greer Ltd.

Growth Drivers:
  • Increasing Prevalence of Peanut Allergy
Restraints & Challenges:
  • High Cost of Peanut Allergy Drug

Figure 2.North America, Europe, and Australia Peanut Allergy Treatment Market Share (%), By Route of Administration, 2022.

North America, Europe, and Australia Peanut Allergy Treatment  | Coherent Market Insights

Increasing product approvals for treatment of peanut allergy are expected to drive market growth during the forecast period.

Increasing product approvals for treatment of peanut allergy are expected to drive the North America, Europe, and Australia Peanut Allergy Treatment Market growth during the forecast period. For instance, In January 2020, Aimmune Therapeutics, Inc., a biopharmaceutical company engaged in developing and commercializing treatments for potentially life-threatening food allergies, announced that the U.S. Food and Drug Administration (FDA) approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. Palforzia is the first approved treatment for patients with peanut allergy.

North America, Europe, and Australia Peanut Allergy Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Lockdown was imposed in several countries globally, which had a negative impact on the economy of the private healthcare sector globally. This lockdown resulted in the closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of products. Thus, COVID-19 pandemic has affected the economy in three main ways: by directly affecting the production and demand, by creating disruptions in distribution channels, and by its financial impact on firms and financial markets. Supply chain and manufacturing activities in North America, Asia Pacific, Europe, and other global regions had been disrupted due to lockdown. Moreover, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources, which were required to ensure safety in hospitals and provide treatment to patients with other diseases, which has also impacted the overall healthcare market negatively. One of the biggest challenges is regarding the supply of raw materials required for manufacturing drugs due to irregularities in the transportation system. Furthermore, due to the increasing number of patients suffering from COVID-19 and other life-threatening illnesses, product distributors are seeing erratic demand for products from retailers.

North America, Europe, and Australia Peanut Allergy Treatment Market: Restraint

The high cost of peanut allergy drug is expected to hinder the growth of North America, Europe, and Australia peanut allergy treatment market over the forecast period. Palforzia is the only treatment approved by the U.S. Food and Drug Administration for children in age group of 4 to 17 years, allergic to peanuts. In January 2020, the U.S. FDA approved palfori allergan powder to mitigate allergic reactions, including anaphylaxis, which may occur with accidental exposure to peanuts. Palforzia costs from US$ 2.77 to US$ 35.60 per unit, depending on the different dosages (Powder for oral administration supplied in 0.5 mg, 1 mg, 10 mg, 20 mg and 100 mg Capsules or 300 mg Sachets.). Monthly cost of palforzia is around US$ 890 and an annual price of Palforzia is approximately US$ 11,000 per year. Thus, the high cost of peanut allergy drug makes it unaffordable for patients and this unaffordability of drug by patients is expected to hamper the market growth.

Key Players

Key players operating in market the market include DBV Technologies, Aimmune Therapeutics, Inc., Prota Therapeutics Pty Ltd., COUR Pharmaceuticals, BlueWillow Biologics, HAL Allergy B.V., Allergy Therapeutics PLC., Novartis AG, Regeneron Pharmaceuticals, Inc., Vedanta Biosciences, Inc., Cambridge Allergy Ltd. (Camallergy), Angany Inc., Moonlight Therapeutics Inc., Allero Therapeutics B.V., Sanofi, Johnson & Johnson, Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Bayer AG, Aurobindo Pharma Limited., Astellas Pharma Inc., Siolta Therapeutics, DESENTUM OY, ALK, Immunomic Therapeutics, Inc., and Stallergenes Greer Ltd.

Peanut allergy is an allergic response by individual on exposure to peanuts. The most severe allergic reaction to peanuts is anaphylaxis a life-threatening whole-body response to an allergen. Anaphylaxis should be treated immediately with epinephrine (adrenaline), typically administered in an auto-injector. Diagnosing a peanut allergy can be complicated. Symptoms can vary from person to person, and a single individual may not always experience the same symptoms during every reaction.

Market Dynamics

Key players operating in the North America, Europe, and Australia peanut allergy treatment market are focusing on adoption of growth strategies such as product approval for the treatment of peanut allergy which are expected to drive market growth during the forecast period. For instance, In September 2021, COUR Pharmaceuticals, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for evaluation of COUR's CNP-201 in a proof-of-concept (Phase 1 / 2) study in people who are allergic to peanuts. Moreover, increasing adoption of inorganic growth strategies by market players and government organizations is expected to drive the market growth over the forecast period. For instance, in December 2021, the National Health Service, U.K., announced that the department of health signed an agreement with Aimmune Therapeutics, Inc., a Nestlé Health Science company to provide Palforzia in the U.K. The U.K. will be the first country to receive Palforzia in Europe.

Key features of the study:

  • This report provides in-depth analysis of the North America, Europe, and Australia peanut allergy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the North America, Europe, and Australia peanut allergy treatment market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, and Strategies
  • Key companies covered as a part of this study include, DBV Technologies DBV Technologies, Aimmune Therapeutics, Inc., Prota Therapeutics Pty Ltd., COUR Pharmaceuticals, BlueWillow Biologics, HAL Allergy B.V., Allergy Therapeutics PLC., Novartis AG, Regeneron Pharmaceuticals, Inc., Vedanta Biosciences, Inc., Cambridge Allergy Ltd. (Camallergy), Angany Inc., Moonlight Therapeutics Inc., Allero Therapeutics B.V., Sanofi, Johnson & Johnson, Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Bayer AG, Aurobindo Pharma Limited., Astellas Pharma Inc., Siolta Therapeutics, DESENTUM OY, ALK, Immunomic Therapeutics, Inc., and Stallergenes Greer Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The North America, Europe, and Australia peanut allergy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America, Europe, and Australia peanut allergy treatment market.

Detailed Segmentation:

  • North America, Europe, and Australia Peanut Allergy Treatment Market, By Drug Type :
    • Epinephrine
    • Antihistamine
      • Loratadine
      • Diphenhydramine
      • Others
    • Palforzia
    • Pipeline Drugs
      • Viaskin Peanut
      • Ligelizumab
      • CA002
      • PRT120
      • Dupilumab
  • North America, Europe, and Australia Peanut Allergy Treatment Market, By Route of Administration :
    • Oral
    • Parenteral
    • Intranasal
    • Epicutaneous
  • North America, Europe, and Australia Peanut Allergy Treatment Market, By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • North America, Europe, and Australia Peanut Allergy Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Northeast
        • Southwest
        • West
        • Southeast
        • Midwest
        • Canada
    • Europe
      • By Country
        • France
        • Italy
        • Spain
        • Switzerland
        • Netherlands
        • Austria
        • Czech & Slovakia
        • Rest of Europe
        • Australia
  • Company Profiles
    • DBV Technologies.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Aimmune Therapeutics, Inc.
    • Prota Therapeutics Pty Ltd.
    • COUR Pharmaceuticals
    • BlueWillow Biologics
    • HAL Allergy B.V.
    • Allergy Therapeutics PLC.
    • Novartis AG
    • Regeneron Pharmaceuticals, Inc.
    • Vedanta Biosciences, Inc.
    • Cambridge Allergy Ltd. (Camallergy)
    • Angany Inc.
    • Moonlight Therapeutics Inc.
    • Allero Therapeutics B.V.
    • Sanofi
    • Johnson & Johnson
    • Viatris Inc. (Mylan N.V.)
    • Sun Pharmaceutical Industries Ltd.
    • Bayer AG
    • Aurobindo Pharma Limited.
    • Astellas Pharma Inc.
    • Siolta Therapeutics
    • DESENTUM OY
    • ALK
    • Immunomic Therapeutics, Inc.
    • Stallergenes Greer Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The North America, Europe, and Australia Peanut Allergy Treatment Market size is estimated to be valued at US$ 1,252.6 million in 2022 and is expected to exhibit a CAGR of 11.7% between 2022 and 2030.
Factor such as increasing prevalence of peanut allergy is expected to drive market growth over the forecast period.
Epinephrine segment is expected to hold a major market share during the forecast period.
The major factors hampering growth of the market include High cost of peanut allergy drug.
Major players operating in the market are DBV Technologies, Aimmune Therapeutics, Inc., Prota Therapeutics Pty Ltd., COUR Pharmaceuticals, BlueWillow Biologics, HAL Allergy B.V., Allergy Therapeutics PLC., Novartis AG, Regeneron Pharmaceuticals, Inc., Vedanta Biosciences, Inc., Cambridge Allergy Ltd. (Camallergy), Angany Inc., Moonlight Therapeutics Inc., Allero Therapeutics B.V., Sanofi, Johnson & Johnson, Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Bayer AG, Aurobindo Pharma Limited., Astellas Pharma Inc., Siolta Therapeutics, DESENTUM OY, ALK, Immunomic Therapeutics, Inc., and Stallergenes Greer Ltd.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo